Clinical Trial Update: Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase I study evaluating ixabepilone plus lapatinib, with or without capecitabine, in HER2-positive breast cancer; the trial was terminated with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ixempra (ixabepilone)
• Tykerb (lapatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: R-Pharm | Conditions: Locally Advanced or Metastatic Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2011-05-03